COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
COLLEGIUM PHARMACEUTICAL, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.01−0.18 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $746.92M
- P/E (TTM)
- 18.6
- Dividend yield
- –
COLLEGIUM PHARMACEUTICAL, INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belbuca | $221.65M | $211.27M | $182.10M | $126.46M | – | – | – | – | – | – | 28.4% | +4.9% |
| Xtampza ER | $199.31M | $191.33M | $177.37M | – | – | – | – | – | – | – | 25.5% | +4.2% |
| Jornay PM | $148.86M | $37.24M | $0 | – | – | – | – | – | – | – | 19.1% | +299.7% |
| Nucynta IR | $115.31M | $100.74M | $108.15M | – | – | – | – | – | – | – | 14.8% | +14.5% |
| Nucynta ER | $80.99M | $75.77M | $82.65M | – | – | – | – | – | – | – | 10.4% | +6.9% |
| Symproic and other | $14.45M | $15.10M | $16.50M | – | – | – | – | – | – | – | 1.9% | -4.3% |
| Xtampza ER | – | $191.33M | $177.37M | $138.80M | $103.71M | $127.98M | $105.01M | $69.38M | $28.48M | $1.71M | – | – |
| Nucynta Products | – | – | – | – | $173.16M | $182.03M | $191.69M | $211.03M | – | – | – | – |
| Nucynta IR | – | $100.74M | $108.15M | $112.06M | $102.22M | $116.32M | $117.68M | $129.92M | – | – | – | – |
| Nucynta ER | – | $75.77M | $82.65M | $72.42M | $70.94M | $65.71M | $74.01M | $81.11M | – | – | – | – |
| Symproic | – | $15.10M | $16.50M | $12.27M | – | – | – | – | – | – | – | – |
| Other | – | – | – | $1.93M | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Collegium Pharmaceutical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.